Loading...
Market
Story
Novavax Secures $500M in Sanofi Vaccine Deal, Stock Surges 40%, Sanofi Takes 4.9% Stake
May 10, 2024, 09:50 AM
Novavax has entered into a significant partnership with Sanofi, involving a co-exclusive licensing agreement to co-commercialize a COVID-19 vaccine and develop novel COVID-19-Influenza combination vaccines. As part of the deal, Novavax will receive $500 million upfront and Sanofi will make a minority 4.9% equity investment in Novavax, valued at approximately $70 million. This deal has led to a 40% surge in Novavax's stock price.
View original story
Similar markets
Approved in USA • 25%
Approved in EU • 25%
Approved in both USA and EU • 25%
Not approved in either • 25%
Top performer • 33%
Average performer • 34%
Below average performer • 33%
Over 50 countries • 25%
30-50 countries • 25%
10-29 countries • 25%
Under 10 countries • 25%
Becomes a top 5 vaccine company • 25%
Remains outside top 5 but improves position • 25%
No significant change in market position • 25%
Declines in market position • 25%
Below 50% effective • 33%
50% to 75% effective • 34%
Above 75% effective • 33%
Pharmaceutical Company • 33%
University Research Team • 33%
Government Health Agency • 34%